CClinicalTrials.gg
Status unknownNCT03458949Updated Jul 2, 2018

Pilot Study in a Company in Maine-et-Loire to Evaluate the Feasibility, Acceptability, and Impact on the Participation Rate of Awareness of Colorectal Cancer Screening by Occupational Health Teams

An interventional study of awareness campaign in Colorectal Cancer, sponsored by University Hospital, Angers. Status unknown at 1 site in France. Open to participants aged 50 Years to 66 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-02.

Sponsored by University Hospital, Angers · Not applicable, Interventional, and Screening

The sponsor has not verified this record recently (last verified Jun 2018), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
1,400
Allocation
Not applicable
Ages
50 Years to 66 Years
Sex
All
01

Study summary

The main objective of this pilot study is to implement an awareness campaign for colorectal cancer screening in the workplace, in partnership with the staff of the occupational health service of one of the largest companies in Maine-Loire , and to evaluate the impact of this action on the participation rate of colorectal cancer screening among employees.

02

Conditions studied

  • Colorectal Cancer
03

Who can participate

Ages eligible
50 Years to 66 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • The study population is made up of the employees of the CHU d'Angers included in the target population of organized colorectal cancer screening in the Maine-et-Loire so employees aged 50 and over.

Exclusion criteria

Exclusion Criteria:

  • The criteria for non-inclusion are those of organized screening for colorectal cancer taking into account the active population:
  • Age \<50 years and> 67 years
  • Personal or family history of polyps or colorectal cancer
  • Personal history of intestinal disease already undergoing colonoscopy surveillance (chronic inflammatory bowel disease, HNPCC syndrome, familial adenomatous polyposis)
  • Known genetic disease with risk of developing colorectal cancer.
04

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,400 participants (estimated)

Interventions

  • Otherawareness campaign

    awareness campaign for colorectal cancer screening in the workplace

05

What researchers measure

Primary outcomes

  1. variation of the rate of participation in colorectal cancer screening

    effective variation (after versus prior to awareness raising) of the overall rate of participation in colorectal cancer screening among employees of the company after 2 years.

    Time frame: 2 years

06

Study locations

1 of 1 sites recruiting
  • Santé au Travail CHU Angers
    Angers, France
    • Pierrre RUCAY, MD · Contact
    Recruiting
07

Registry details

Key details

Study ID
NCT03458949
Lead sponsor
University Hospital, Angers
Responsible party
Sponsor
First posted
Mar 8, 2018
Start date
Jun 18, 2018
Primary completion
Apr 2020 (estimated)
Completion
Jan 2021 (estimated)
Last update
Jul 2, 2018

Study contacts

François-Xavier Caroli-Bosc, MDPhD
Contact
FX.Caroli-Bosc@chu-angers.fr
+33 2 41 35 60 54
François-Xavier Caroli-Bosc, MDPhD
principal investigator · University Hospital, Angers

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion